Chroma Medicine Presents Preclinical In Vivo Data Showing Durable Cholesterol Reduction with a PCSK9-Targeted Epigenetic Editor at the 2023 AHA Scientific Sessions
This first presentation of non-human primate (NHP) data highlights the potential of Chroma’s epigenetic editors to achieve specific and robust results after a single administration, without cutting or nicking the DNA In NHPs, Chroma’s epigenetic editor achieved efficient reductions in bl
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kenvue Inc. – KVUE
NEW YORK, Nov. 11, 2023 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Kenvue Inc. (“Kenvue” or the “Company”) (NYSE: KVUE). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adobe, Inc. – ADBE
NEW YORK, Nov. 11, 2023 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Adobe, Inc. (“Adobe” or the “Company”) (NASDAQ: ADBE). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 798
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fifth Third Bancorp – FITB
NEW YORK, Nov. 11, 2023 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Fifth Third Bancorp (“Fifth Third” or the “Company”) (NASDAQ: FITB). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476
Pet Supplies Plus and Natural Balance® Join Forces to Gift $50,000 Veteran’s Day Donation to Patriot PAWS
Largest Pet Retail Franchise and Premium Pet Food Maker Help Provide Service Dogs to Deserving Veterans PROSPER, Texas, Nov. 11, 2023 /PRNewswire/ — Pet Supplies Plus, the largest and most trusted pet retail franchise, has once again joined forces with Natural Balance® to raise awareness of t
Kyverna Therapeutics Congratulates the Teams at the Universities of Bochum and Magdeburg for a Late Breaker Case Report in a Patient with Refractory Myasthenia Gravis Treated with Investigational KYV-101
The severely disabled and treatment-refractory patient was discharged without symptoms three weeks after KYV-101 infusion and was fully mobile 60 days after, with no observed adverse events related to CAR T-cell therapy The late breaker abstract was presented on November 11, 2023 at the 96th Congres
Kyverna Therapeutics Congratulates Scientific Advisory Board Member Peter A. Merkel, M.D., M.P.H. on Receiving the 2023 ACR Distinguished Clinical Investigator Award
Dr. Merkel will receive the award during the 2023 ACR Convergence Meeting in San Diego, CA for his outstanding contributions to the field of rheumatology EMERYVILLE, Calif., Nov. 11, 2023 /PRNewswire/ — Kyverna Therapeutics, Inc. (Kyverna), a patient-centered clinical-stage biopharmaceutical c
Fapon Inaugurates State-of-the-Art R&D Center in Lexington, MA
LEXINGTON, Mass., Nov. 11, 2023 /PRNewswire/ — Fapon, a global leading life sciences organization, is thrilled to announce the grand opening of its US-based Research and Development (R&D) Center, strategically located in Lexington, Massachusetts. This Center represents Fapon’s unwave
Post Hoc Analysis Showed CIMZIA® (Certolizumab Pegol) Resulted in Meaningful Efficacy for RA Patients with High Levels of Rheumatoid Factor (RF)
A post hoc analysis from the EXXELERATE Phase 4 trial showed that 65.7 percent of CIMZIA-treated patients with rheumatoid arthritis (RA) and high rheumatoid factor (RF) levels achieved low disease activity at Week 1041CIMZIA maintained drug concentrations and achieved Low Disease Activity regardless
/R E M I N D E R — Media Advisory – Prime Minister’s itinerary for Saturday, November 11, 2023/
OTTAWA, ON, Nov. 10, 2023 /CNW/ – Note: All times local National Capital Region, Canada Private meetings 10:45 a.m. The Prime Minister will participate in the National Remembrance Day Ceremony. The Minister of Veterans Affairs and Associate Minister of National Defence, Ginette Petitpas